CureVac NV
NASDAQ:CVAC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Hubei Three Gorges Tourism Group Co Ltd
SZSE:002627
|
CN |
CureVac NV
Interest Expense
CureVac NV
Interest Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CureVac NV
NASDAQ:CVAC
|
Interest Expense
€2.3m
|
CAGR 3-Years
10%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Interest Expense
€14.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
48%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Interest Expense
€946k
|
CAGR 3-Years
-3%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Interest Expense
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Heidelberg Pharma AG
XETRA:HPHA
|
Interest Expense
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Formycon AG
XETRA:FYB
|
Interest Expense
€1.1m
|
CAGR 3-Years
203%
|
CAGR 5-Years
108%
|
CAGR 10-Years
64%
|
|
CureVac NV
Glance View
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.
See Also
What is CureVac NV's Interest Expense?
Interest Expense
2.3m
EUR
Based on the financial report for Dec 31, 2024, CureVac NV's Interest Expense amounts to 2.3m EUR.
What is CureVac NV's Interest Expense growth rate?
Interest Expense CAGR 5Y
23%
Over the last year, the Interest Expense growth was -3%. The average annual Interest Expense growth rates for CureVac NV have been 10% over the past three years , 23% over the past five years .
